ViroPharma (VPHM) Posts Q3 EPS of $0.26, In-Line with Estimates
More News related to VPHM
- Personalized Pharmaceutical Systems Announces Sale of Angioedema Clinical Prediction Guide to Viropharma Incorporated
- ViroPharma to Present at Three November Healthcare Conferences
- ThinkEquity Upgrades ViroPharma (VPHM) to Buy
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
- Morning Movers 10/28: CSBC, QTM, ANIK, RSYS, PEET, WSII Higher; CALC, KSP, PSYS, VCLK, VPHM, GT Lower
ViroPharma (NASDAQ: VPHM) reports Q3 EPS of $0.26, in-line the analyst estimate of $0.26. Revenue for the quarter was $81 million, which compares to the estimate of $84.22 million.
Related Categories
EarningsStocks Mentioned
+0.25Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
